Skip to main content

An open-label, Phase 1b study to evaluate the safety and tolerability of eflornithine plus temozolomide in patients with newly diagnosed glioblastoma

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Orbus Therapeutics, Inc.

Start Date

January 11, 2024

End Date

January 31, 2028
 

Administered By

Duke Cancer Institute

Awarded By

Orbus Therapeutics, Inc.

Start Date

January 11, 2024

End Date

January 31, 2028